NASDAQ:BIIB Biogen (BIIB) Stock Price, News & Analysis $250.34 -3.50 (-1.38%) As of 02:04 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Biogen Stock (NASDAQ:BIIB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Biogen alerts:Sign Up Key Stats Today's Range$246.15▼$252.2750-Day Range$209.15▼$253.8452-Week Range$138.00▼$254.41Volume497,677 shsAverage Volume1.21 million shsMarket Capitalization$36.99 billionP/E Ratio44.31Dividend YieldN/APrice Target$241.89Consensus RatingModerate Buy Company Overview Biogen Inc. is a biotechnology company that discovers, develops and commercializes therapies for neurological and neurodegenerative diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, amyotrophic lateral sclerosis and other serious medical conditions. The company’s portfolio includes multiple sclerosis treatments such as Tecfidera, Vumerity, Tysabri, Plegridy and Avonex, as well as Spinraza for spinal muscular atrophy. Biogen also markets Leqembi, an Alzheimer’s disease treatment developed in collaboration with Eisai, and works with partners to advance additional therapies and biosimilars. Biogen was founded in 1978 and is headquartered in Cambridge, Massachusetts. The company serves patients and healthcare providers in markets around the world through its research, manufacturing and commercial operations. Christopher Viehbacher has served as Biogen’s president and chief executive officer since 2023.AI Generated. May Contain Errors. Read More Biogen Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks58th Percentile Overall ScoreBIIB MarketRank™: 2.91926702961 of 5 starsBiogen scored higher than 58% of companies evaluated by MarketBeat, and ranked 387th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.3 / 5Analyst RatingModerate Buy Consensus RatingBiogen has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on 1 strong buy rating, 19 buy ratings, 11 hold ratings, and 1 sell rating.Upside/DownsideThe consensus price target for Biogen is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageBiogen has been the subject of 20 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Biogen's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth29.24% Earnings GrowthEarnings for Biogen are expected to grow by 29.24% in the coming year, from $12.31 to $15.91 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biogen is 44.34, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.75.Price to Earnings Ratio vs. SectorThe P/E ratio of Biogen is 44.34, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.73.Price to Earnings Growth RatioBiogen has a PEG Ratio of 2.68. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioBiogen has a P/B Ratio of 2.01. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Biogen's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.05% of the float of Biogen has been sold short.Short Interest Ratio / Days to CoverBiogen has a short interest ratio ("days to cover") of 4.87.Change versus previous monthShort interest in Biogen has recently increased by 2.55%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBiogen does not currently pay a dividend.Dividend GrowthBiogen does not have a long track record of dividend growth. News and Social Media4.4 / 5News Sentiment1.08 News SentimentBiogen has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 35 news articles for Biogen this week, compared to 11 articles on an average week.Search Interest17 people have searched for BIIB on MarketBeat in the last 30 days. This is an increase of 13% compared to the previous 30 days.MarketBeat Follows4 people have added Biogen to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Biogen insiders have not sold or bought any company stock.Percentage Held by Insiders0.25% of the stock of Biogen is held by insiders.Percentage Held by Institutions87.93% of the stock of Biogen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Biogen's insider trading history. Receive BIIB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biogen and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BIIB Stock News HeadlinesBiogen (BIIB) Surges 5.3%: Is This an Indication of Further Gains?3 hours ago | finance.yahoo.comWedbush Remains a Hold on Biogen (BIIB)October 22 at 8:46 AM | theglobeandmail.comReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.October 23 at 1:00 AM | Base Camp Trading (Ad)Contrasting Biogen (NASDAQ:BIIB) & Soligenix (NASDAQ:SNGX)October 22 at 4:31 AM | americanbankingnews.comBiogen (NASDAQ:BIIB) Stock Gets Price Target Boost from Wells Fargo & CompanyOctober 22 at 2:18 AM | americanbankingnews.comBiogen (NASDAQ:BIIB) Sets New 1-Year High on Analyst UpgradeOctober 22 at 1:21 AM | americanbankingnews.comThe Zacks Analyst Blog Highlights BridgeBio Pharma, Intellia Therapeutics, Biogen and Viking TherapeuticsOctober 21 at 2:02 PM | finance.yahoo.comBiogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseOctober 21 at 2:02 PM | finance.yahoo.comSee More Headlines BIIB Stock Analysis - Frequently Asked Questions How have BIIB shares performed this year? Biogen's stock was trading at $175.99 at the start of the year. Since then, BIIB shares have increased by 42.4% and is now trading at $250.6440. How were Biogen's earnings last quarter? Biogen Inc. (NASDAQ:BIIB) posted its earnings results on Wednesday, July, 29th. The biotechnology company reported $3.60 earnings per share for the quarter, beating analysts' consensus estimates of $2.94 by $0.66. Biogen's quarterly revenue was up 3.4% compared to the same quarter last year. Read the conference call transcript. Does Biogen have any subsidiaries? The following companies are subsidiaries of Biogen: Nightstar Therapeutics plc, Convergence Pharmaceuticals, TYSABRI, Stromedix Inc., Panima Pharmaceuticals AG, Syntonix Pharmaceuticals Inc., Fumapharm, and others. Who are Biogen's major shareholders? Top institutional investors of Biogen include Robeco Institutional Asset Management B.V. (0.44%), Sumitomo Mitsui DS Asset Management Company Ltd (0.23%), Yousif Capital Management LLC (0.18%) and State of Alaska Department of Revenue (0.17%). Insiders that own company stock include Eric K Rowinsky, Nicole Murphy, Stephen A Sherwin, Stephen A Sherwin, Stephen A Sherwin, Priya Singhal and Rachid Izzar. View institutional ownership trends. How do I buy shares of Biogen? Shares of BIIB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Biogen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Biogen investors own include NVIDIA (NVDA), Tesla (TSLA), Netflix (NFLX), Gilead Sciences (GILD), Alibaba Group (BABA), Bristol Myers Squibb (BMY) and Micron Technology (MU). Company Calendar Last Earnings7/29/2026Today10/23/2026Next Earnings (Estimated)10/28/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (6m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 BIIB's financial health is in the Green zone, according to TradeSmith. BIIB has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:BIIB CIK875045 Webwww.biogen.com Phone(617) 679-2000Fax617-679-2617Employees7,500Year Founded1978Price Target and Rating Average Price Target for Biogen$241.89 High Price Target$310.00 Low Price Target$175.00 Potential Upside/Downside-3.4%Consensus RatingModerate Buy Rating Score (0-4)2.63 Research Coverage32 Analysts Profitability EPS (Trailing Twelve Months)$5.65 Trailing P/E Ratio44.31 Forward P/E Ratio20.34 P/E Growth2.68Net Income$1.29 billion Net Margins8.32% Pretax Margin10.09% Return on Equity11.18% Return on Assets6.88% Debt Debt-to-Equity Ratio0.39 Current Ratio1.87 Quick Ratio1.26 Sales & Book Value Annual Sales$9.89 billion Price / Sales3.74 Cash Flow$23.51 per share Price / Cash Flow10.65 Book Value$124.45 per share Price / Book2.01Miscellaneous Outstanding Shares147,750,000Free Float147,385,000Market Cap$36.99 billion OptionableOptionable Beta0.09 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:BIIB) was last updated on 10/23/2026 by MarketBeat.com Staff. From Our PartnersTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billi...Banyan Hill Publishing | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biogen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biogen With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
